Today: 29 April 2026
Nike stock steadies in premarket after CEO Elliott Hill discloses $1 million share buy
31 December 2025
2 mins read

Nike stock steadies in premarket after CEO Elliott Hill discloses $1 million share buy

NEW YORK, December 31, 2025, 04:30 ET — Premarket

  • Nike shares were little changed in premarket trading after an SEC filing showed CEO Elliott Hill bought stock in the open market.
  • A separate filing showed co-founder Philip Knight received 4.5 million convertible Class A shares in a private distribution.
  • Investors remain focused on whether Nike can rebuild margins and regain traction in China.

Nike shares were little changed in premarket trading on Wednesday after a regulatory filing showed Chief Executive Elliott Hill bought about $1 million of the sportswear maker’s stock. The shares were last down fractionally at $61.19.

The insider buying matters because investors often read open-market purchases by executives as a sign of confidence, especially when a company is trying to stabilize results. For Nike, that confidence test is playing out against a backdrop of margin pressure and uneven demand across regions.

It also lands on a thinly traded part of the calendar, with investors closing out the year and positioning for the New Year holiday. That can magnify day-to-day moves in heavily watched consumer names like Nike.

In a Form 4 — an SEC document insiders file to disclose stock transactions — Hill reported buying 16,388 shares of Nike Class B common stock on Dec. 29 at a weighted average price of $61.10. The filing showed the purchases were executed in multiple trades between $61.09 and $61.10, and left him with 241,587 shares.

Hill is both president and CEO, according to the filing. Investors often track insider activity closely when shares are near recent lows, since executives typically have a front-row view of demand, product cycles and inventory.

A separate Form 4 showed Nike co-founder and Chairman Emeritus Philip Knight acquired 4.5 million shares of Nike’s Class A common stock, which is convertible into Class B shares on a one-for-one basis. The filing said the shares were received in a private pro rata distribution from Swoosh, LLC.

The disclosures follow Nike’s most recent quarterly report, which highlighted the pressure points investors have been debating since the company’s reset began. Nike reported revenue of $12.427 billion for the quarter ended Nov. 30, and said gross margin fell 300 basis points — or 3 percentage points — to 40.6%, primarily due to higher tariffs in North America; net income fell 32% to $0.8 billion, with diluted earnings per share down 32% to $0.53.

On the same earnings cycle, Nike’s weak performance in China remained a key concern. “It is a concern that the China results continue to be so poor,” Morningstar analyst David Swartz said, as Nike faces sharper competition from newer brands such as On and Deckers’ Hoka. Reuters

That backdrop is likely to keep the focus on margin repair — including how quickly Nike can move past heavy discounting — and whether demand in China begins to stabilize. Investors are also watching whether the company’s product reset can translate into cleaner inventory and a firmer pricing environment.

U.S. stock markets are set to operate normal hours on New Year’s Eve, while bond markets close early at 2 p.m. ET, according to Barron’s. Markets will be closed on New Year’s Day.

Stock Market Today

  • Align Technology Beats Q1 Sales Estimates, Reports $1.04 Billion Revenue
    April 29, 2026, 4:41 PM EDT. Align Technology (NASDAQ:ALGN) reported a strong Q1 CY2026 with 6.2% year-on-year sales growth to $1.04 billion, exceeding Wall Street revenue estimates by 1.8%. Adjusted earnings per share came in at $2.58, 12.8% above analyst consensus. The company's operating income also beat expectations by 11.1%, driven by solid operating margins of 21.5%. Despite these gains, Align projected next quarter revenue around $1.05 billion, aligning with market forecasts. The company's five-year annualized revenue growth of 7.8% outpaces healthcare sector averages, but recent two-year growth has slowed to 2.3%, raising concerns about demand trends. Analysts project modest growth going forward, around 3%, indicating cautious investor sentiment on new product impact.

Latest article

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

29 April 2026
Nebius Group N.V. shares rose 5.3% to $142.73 Wednesday as Meta Platforms raised its 2026 capital spending forecast by up to $10 billion, citing higher data center costs. Nebius has a contract to supply Meta with up to $27 billion in AI cloud capacity. Fourth-quarter 2025 revenue jumped 547% to $227.7 million, but the company reported a net loss of $249.6 million.
Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

29 April 2026
Phillips 66 reported an adjusted first-quarter profit of $200 million, or 49 cents per share, beating analyst forecasts of a loss. Strong refining margins and 95% plant utilization offset $839 million in hedge-related losses. Shares rose over 6% after the results. The company also completed its acquisition of Lindsey Oil Refinery assets in the UK.
Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

29 April 2026
Extreme Networks shares surged 28% after reporting fiscal Q3 revenue of $316.9 million, up 11%, and non-GAAP earnings of 26 cents per share, both above estimates. The company forecast Q4 revenue of $330–$335 million, topping FactSet’s $326.9 million estimate. SaaS annual recurring revenue rose 28.6% to $236.4 million. Net income climbed to $10.6 million from $3.5 million a year earlier.
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Previous Story

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Ondas stock slips in premarket after 2x leveraged ONDS ETF launch sparks heavy trading
Next Story

Ondas stock slips in premarket after 2x leveraged ONDS ETF launch sparks heavy trading

Go toTop